Health economic modeling for Alzheimer's disease: Expert perspectives

F. Landeiro; J. Morton; A. Gustavsson; M. Potashman; P. Lecomte; M. Belger; R. Thompson; E. Roncancio-Diaz; G. Jhuti; C. Butler; L. Jonsson; R. Handels; A.M. Gray; the ROADMAP Study

doi:10.1002/trc2.12360

Health economic modeling for Alzheimer's disease: Expert perspectives

F. Landeiro^*, J. Morton, A. Gustavsson, M. Potashman, P. Lecomte, M. Belger, R. Thompson, E. Roncancio-Diaz, G. Jhuti, C. Butler, L. Jonsson, R. Handels, A.M. Gray, the ROADMAP Study

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The successful development of an economic model for the evaluation of future Alzheimer's disease (AD) interventions is critical to accurately inform policy makers and payers. As our understanding of AD expands, this becomes an increasingly complex and challenging goal. Advances in diagnostic techniques for AD and the prospect of disease-modifying treatments raise an urgent need to define specifications for future economic models and to ensure that the necessary data to populate them are available. This Perspective article provides expert opinions from health economists and governmental agency representatives on how future economic models for AD might be structured, validated, and reported. We aim to stimulate much-needed discussion about the detailed specification of future health economic models for AD.

Original language	English
Article number	e12360
Number of pages	7
Journal	Alzheimer's and Dementia: Translational Research and Clinical Interventions
Volume	8
Issue number	1
DOIs	https://doi.org/10.1002/trc2.12360
Publication status	Published - 2022

Keywords

Alzheimer's disease
CONTINUUM
COST-EFFECTIVENESS
DEMENTIA
MORTALITY
PREDICTORS
costs
dementia
disease-modifying treatment
economic models
model structure
pre-dementia
quality of life
quality-adjusted life years

Access to Document

10.1002/trc2.12360Licence: CC BY-NC-ND

Cite this

Landeiro, F., Morton, J., Gustavsson, A., Potashman, M., Lecomte, P., Belger, M., Thompson, R., Roncancio-Diaz, E., Jhuti, G., Butler, C., Jonsson, L., Handels, R., Gray, A. M., & the ROADMAP Study (2022). Health economic modeling for Alzheimer's disease: Expert perspectives. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 8(1), Article e12360. https://doi.org/10.1002/trc2.12360

@article{e4cdd3e175c54f0c8d8f67e25ec43a68,

title = "Health economic modeling for Alzheimer's disease: Expert perspectives",

abstract = "The successful development of an economic model for the evaluation of future Alzheimer's disease (AD) interventions is critical to accurately inform policy makers and payers. As our understanding of AD expands, this becomes an increasingly complex and challenging goal. Advances in diagnostic techniques for AD and the prospect of disease-modifying treatments raise an urgent need to define specifications for future economic models and to ensure that the necessary data to populate them are available. This Perspective article provides expert opinions from health economists and governmental agency representatives on how future economic models for AD might be structured, validated, and reported. We aim to stimulate much-needed discussion about the detailed specification of future health economic models for AD.",

keywords = "Alzheimer's disease, CONTINUUM, COST-EFFECTIVENESS, DEMENTIA, MORTALITY, PREDICTORS, costs, dementia, disease-modifying treatment, economic models, model structure, pre-dementia, quality of life, quality-adjusted life years",

author = "F. Landeiro and J. Morton and A. Gustavsson and M. Potashman and P. Lecomte and M. Belger and R. Thompson and E. Roncancio-Diaz and G. Jhuti and C. Butler and L. Jonsson and R. Handels and A.M. Gray and {the ROADMAP Study}",

note = "Funding Information: Filipa Landeiro has been funded by a grant from Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020 (ROADMAP). Jasmine Morton: none exist. Anders Gustavsson is a partner of Quantify Research, providing consultancy services to pharmaceutical companies and other private and public organizations and institutions. AG's contribution to ROADMAP was on behalf of Roche Pharmaceuticals. Michele Potashman is an employee of Biogen and owns stock in Biogen. She owns stock in a variety of companies that at times include other pharmaceutical and health care–related companies. Pascal Lecomte is employed by, owns stock in, and has stock options in Novartis Pharma AG. Mark Belger is a full‐time employee and shareholder of Eli Lilly and Company. Robin Thompson is an employee of Biogen and owns stock in Biogen. Emilse Roncancio‐Diaz is employed by GE Healthcare. Gurleen Jhuti is employed by F. Hoffmann‐La Roche Ltd. Christopher Butler: none exist. Linus J{\"o}nsson is employed by H. Lundbeck A/S. Ron Handels has received grants from ROADMAP (Innovative Medicines Initiative 2 Joint Undertaking 2016‐2018); consulting fees from Piramal, Roche, and Eisai; grants from Horizon 2020, JPND Joint Programming Neurodegenerative Disease Research, IMI Innovative Medicines Initiative, and national, European and patient charity funding organizations and private–public collaborations (ZonMw Netherlands; Alzheimer Netherlands; Dutch Flutemetamol Study; Alzheimer Research UK; Swedish National study on Aging and Care; European Brain Council). Alastair M. Gray has received a grant from Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020 (ROADMAP). A.M.G. is partially supported by the National Institute for Health Research Biomedical Research Centre at the University of Oxford (grant number NIHR‐BRC‐1215‐20008). Author disclosures are available in the supporting information. Funding Information: We would like to acknowledge the contributions of Professor Dr. Colin Green (Exeter University, UK), Professor Dr. Peter J. Neumann (Tufts Medical Center, US), Professor Dr. Anders Wimo (Karolinska Institutet, SE), and Professor Dr. Bengt Winblad (Karolinska Institutet, SE), who were not involved in ROADMAP, for their expert opinions on health economic evaluation and modeling during a face-to-face group discussion meeting. We would also like to acknowledge the members of the Regulatory, HTA, and payer Expert Advisory Group within ROADMAP for their expert opinions during telephone and face-to-face group discussion meetings: Jacoline Bouvy (National Institute for Health and Care Excellence, UK), Anja Schiel (Norwegian Medicines Agency, NO), Christine Gispen de Wied (Medicines Evaluation Board, NL), Raj Long (Gates Foundation, UK), Entela Xoxi (Catholic University Sacro Cuore, IT), Amr Makady (Zorginstituut Nederland, NL), Niklas Hedberg (Tandv{\aa}rds-Och L{\"a}kemedelsf{\"o}rm{\aa}nsverket, SE). Medical writing support provided by Winfield Consulting was funded by GE Healthcare. The medical writers{\textquoteright} role was to provide support in converting a report into a manuscript. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020 (“ROADMAP”). This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The funding source had no involvement in the development of this manuscript. Funding Information: We would like to acknowledge the contributions of Professor Dr. Colin Green (Exeter University, UK), Professor Dr. Peter J. Neumann (Tufts Medical Center, US), Professor Dr. Anders Wimo (Karolinska Institutet, SE), and Professor Dr. Bengt Winblad (Karolinska Institutet, SE), who were not involved in ROADMAP, for their expert opinions on health economic evaluation and modeling during a face‐to‐face group discussion meeting. We would also like to acknowledge the members of the Regulatory, HTA, and payer Expert Advisory Group within ROADMAP for their expert opinions during telephone and face‐to‐face group discussion meetings: Jacoline Bouvy (National Institute for Health and Care Excellence, UK), Anja Schiel (Norwegian Medicines Agency, NO), Christine Gispen de Wied (Medicines Evaluation Board, NL), Raj Long (Gates Foundation, UK), Entela Xoxi (Catholic University Sacro Cuore, IT), Amr Makady (Zorginstituut Nederland, NL), Niklas Hedberg (Tandv{\aa}rds‐Och L{\"a}kemedelsf{\"o}rm{\aa}nsverket, SE). Medical writing support provided by Winfield Consulting was funded by GE Healthcare. The medical writers{\textquoteright} role was to provide support in converting a report into a manuscript. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020 (“ROADMAP”). This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The funding source had no involvement in the development of this manuscript. Publisher Copyright: {\textcopyright} 2022 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",

year = "2022",

doi = "10.1002/trc2.12360",

language = "English",

volume = "8",

journal = "Alzheimer's and Dementia: Translational Research and Clinical Interventions",

issn = "2352-8737",

publisher = "Elsevier Inc.",

number = "1",

}

Landeiro, F, Morton, J, Gustavsson, A, Potashman, M, Lecomte, P, Belger, M, Thompson, R, Roncancio-Diaz, E, Jhuti, G, Butler, C, Jonsson, L, Handels, R, Gray, AM & the ROADMAP Study 2022, 'Health economic modeling for Alzheimer's disease: Expert perspectives', Alzheimer's and Dementia: Translational Research and Clinical Interventions, vol. 8, no. 1, e12360. https://doi.org/10.1002/trc2.12360

TY - JOUR

T1 - Health economic modeling for Alzheimer's disease: Expert perspectives

AU - Landeiro, F.

AU - Morton, J.

AU - Gustavsson, A.

AU - Potashman, M.

AU - Lecomte, P.

AU - Belger, M.

AU - Thompson, R.

AU - Roncancio-Diaz, E.

AU - Jhuti, G.

AU - Butler, C.

AU - Jonsson, L.

AU - Handels, R.

AU - Gray, A.M.

AU - the ROADMAP Study

N1 - Funding Information: Filipa Landeiro has been funded by a grant from Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020 (ROADMAP). Jasmine Morton: none exist. Anders Gustavsson is a partner of Quantify Research, providing consultancy services to pharmaceutical companies and other private and public organizations and institutions. AG's contribution to ROADMAP was on behalf of Roche Pharmaceuticals. Michele Potashman is an employee of Biogen and owns stock in Biogen. She owns stock in a variety of companies that at times include other pharmaceutical and health care–related companies. Pascal Lecomte is employed by, owns stock in, and has stock options in Novartis Pharma AG. Mark Belger is a full‐time employee and shareholder of Eli Lilly and Company. Robin Thompson is an employee of Biogen and owns stock in Biogen. Emilse Roncancio‐Diaz is employed by GE Healthcare. Gurleen Jhuti is employed by F. Hoffmann‐La Roche Ltd. Christopher Butler: none exist. Linus Jönsson is employed by H. Lundbeck A/S. Ron Handels has received grants from ROADMAP (Innovative Medicines Initiative 2 Joint Undertaking 2016‐2018); consulting fees from Piramal, Roche, and Eisai; grants from Horizon 2020, JPND Joint Programming Neurodegenerative Disease Research, IMI Innovative Medicines Initiative, and national, European and patient charity funding organizations and private–public collaborations (ZonMw Netherlands; Alzheimer Netherlands; Dutch Flutemetamol Study; Alzheimer Research UK; Swedish National study on Aging and Care; European Brain Council). Alastair M. Gray has received a grant from Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020 (ROADMAP). A.M.G. is partially supported by the National Institute for Health Research Biomedical Research Centre at the University of Oxford (grant number NIHR‐BRC‐1215‐20008). Author disclosures are available in the supporting information. Funding Information: We would like to acknowledge the contributions of Professor Dr. Colin Green (Exeter University, UK), Professor Dr. Peter J. Neumann (Tufts Medical Center, US), Professor Dr. Anders Wimo (Karolinska Institutet, SE), and Professor Dr. Bengt Winblad (Karolinska Institutet, SE), who were not involved in ROADMAP, for their expert opinions on health economic evaluation and modeling during a face-to-face group discussion meeting. We would also like to acknowledge the members of the Regulatory, HTA, and payer Expert Advisory Group within ROADMAP for their expert opinions during telephone and face-to-face group discussion meetings: Jacoline Bouvy (National Institute for Health and Care Excellence, UK), Anja Schiel (Norwegian Medicines Agency, NO), Christine Gispen de Wied (Medicines Evaluation Board, NL), Raj Long (Gates Foundation, UK), Entela Xoxi (Catholic University Sacro Cuore, IT), Amr Makady (Zorginstituut Nederland, NL), Niklas Hedberg (Tandvårds-Och Läkemedelsförmånsverket, SE). Medical writing support provided by Winfield Consulting was funded by GE Healthcare. The medical writers’ role was to provide support in converting a report into a manuscript. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020 (“ROADMAP”). This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The funding source had no involvement in the development of this manuscript. Funding Information: We would like to acknowledge the contributions of Professor Dr. Colin Green (Exeter University, UK), Professor Dr. Peter J. Neumann (Tufts Medical Center, US), Professor Dr. Anders Wimo (Karolinska Institutet, SE), and Professor Dr. Bengt Winblad (Karolinska Institutet, SE), who were not involved in ROADMAP, for their expert opinions on health economic evaluation and modeling during a face‐to‐face group discussion meeting. We would also like to acknowledge the members of the Regulatory, HTA, and payer Expert Advisory Group within ROADMAP for their expert opinions during telephone and face‐to‐face group discussion meetings: Jacoline Bouvy (National Institute for Health and Care Excellence, UK), Anja Schiel (Norwegian Medicines Agency, NO), Christine Gispen de Wied (Medicines Evaluation Board, NL), Raj Long (Gates Foundation, UK), Entela Xoxi (Catholic University Sacro Cuore, IT), Amr Makady (Zorginstituut Nederland, NL), Niklas Hedberg (Tandvårds‐Och Läkemedelsförmånsverket, SE). Medical writing support provided by Winfield Consulting was funded by GE Healthcare. The medical writers’ role was to provide support in converting a report into a manuscript. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020 (“ROADMAP”). This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The funding source had no involvement in the development of this manuscript. Publisher Copyright: © 2022 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

PY - 2022

Y1 - 2022

N2 - The successful development of an economic model for the evaluation of future Alzheimer's disease (AD) interventions is critical to accurately inform policy makers and payers. As our understanding of AD expands, this becomes an increasingly complex and challenging goal. Advances in diagnostic techniques for AD and the prospect of disease-modifying treatments raise an urgent need to define specifications for future economic models and to ensure that the necessary data to populate them are available. This Perspective article provides expert opinions from health economists and governmental agency representatives on how future economic models for AD might be structured, validated, and reported. We aim to stimulate much-needed discussion about the detailed specification of future health economic models for AD.

AB - The successful development of an economic model for the evaluation of future Alzheimer's disease (AD) interventions is critical to accurately inform policy makers and payers. As our understanding of AD expands, this becomes an increasingly complex and challenging goal. Advances in diagnostic techniques for AD and the prospect of disease-modifying treatments raise an urgent need to define specifications for future economic models and to ensure that the necessary data to populate them are available. This Perspective article provides expert opinions from health economists and governmental agency representatives on how future economic models for AD might be structured, validated, and reported. We aim to stimulate much-needed discussion about the detailed specification of future health economic models for AD.

KW - Alzheimer's disease

KW - CONTINUUM

KW - COST-EFFECTIVENESS

KW - DEMENTIA

KW - MORTALITY

KW - PREDICTORS

KW - costs

KW - dementia

KW - disease-modifying treatment

KW - economic models

KW - model structure

KW - pre-dementia

KW - quality of life

KW - quality-adjusted life years

U2 - 10.1002/trc2.12360

DO - 10.1002/trc2.12360

M3 - Article

C2 - 36313968

SN - 2352-8737

VL - 8

JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions

JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions

IS - 1

M1 - e12360

ER -